|
KMID : 1141520240390020206
|
|
Endocrinology and Metabolism
2024 Volume.39 No. 2 p.206 ~ p.221
|
|
|
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
|
|
Son Jang-Won
Lim Soo
|
|
|
Abstract
|
|
|
|
Obesity is a significant risk factor for health issues like type 2 diabetes and cardiovascular disease. It often proves resistant to traditional lifestyle interventions, prompting a need for more precise therapeutic strategies. This has led to a focus on signaling pathways and neuroendocrine mechanisms to develop targeted obesity treatments. Recent developments in obesity management have been revolutionized by introducing novel glucagon-like peptide-1 (GLP-1) based drugs, such as semaglutide and tirzepatide. These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-protein?coupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. These receptors are vital in regulating body fat and energy balance. The development of multiagonists, including GLP-1?glucagon and GIP?GLP-1?glucagon receptor agonists, especially with the potential for glucagon receptor activation, marks a significant advancement in the field. This review covers the development and clinical efficacy of various GLP-1-based therapeutics, exploring the challenges and future directions in obesity management.
|
|
|
KEYWORD
|
|
|
Glucagon-like peptide-1 receptor agonists, Glucose-dependent insulinotropic polypeptide, Glucagon, Multiagonist, Obesity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|